Literature DB >> 24283574

DNA/protein binding, molecular docking, and in vitro anticancer activity of some thioether-dipyrrinato complexes.

Rakesh Kumar Gupta1, Gunjan Sharma, Rampal Pandey, Amit Kumar, Biplob Koch, Pei-Zhou Li, Qiang Xu, Daya Shankar Pandey.   

Abstract

Syntheses and characterizations of the arene ruthenium [(η(6)-C6H6)RuCl(4-mtdpm)] (1), [(η(6)-p-MeC6H4Pr(i))RuCl(4-mtdpm)] (2), and structurally analogous rhodium/iridium complexes [(η(5)-C5Me5)RhCl(4-mtdpm)] (3) and [(η(5)-C5Me5)IrCl(4-mtdpm)] (4) [4-mtdpm = 5-(4-methylthiophenyl)dipyrromethene] have been reported. Their identities have been established by satisfactory elemental analyses, electrospray ionization-mass spectrometry (ESI-MS), FT-IR, NMR ((1)H, (13)C), UV/vis, emission spectral, and electrochemical studies. Structure of the representative complex 3 has been authenticated by X-ray single crystal analyses. The complexes 1-4 effectively bind with calf thymus DNA (CT DNA) through intercalative/electrostatic interactions. In addition, these exhibit significant cytotoxicity toward Dalton lymphoma (DL) cell line and cause static quenching of the bovine serum albumin (BSA) fluorophore. The antiproliferative activity, morphological changes, and apoptosis have been evaluated by MTT assay, acridine orange/ethidium bromide (AO/EtBr) fluorescence staining, and DNA ladder assay. Mode of interaction of the complexes with DNA/protein has also been supported by molecular docking. Various studies revealed remarkable decrease in the in vitro DL cell proliferation and induction of the apoptosis by 1-4, which lies in the order 2 > 1 > 4 > 3.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24283574     DOI: 10.1021/ic401662d

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  6 in total

1.  Screening organometallic thiophene containing thiosemicarbazone ruthenium (II/III) complexes as potential anti-tumour agents.

Authors:  Zehra Tavsan; Pelin Köse Yaman; Elif Subasi; Hulya Ayar Kayali
Journal:  J Biol Inorg Chem       Date:  2018-03-22       Impact factor: 3.358

2.  Enantiopure copper(II) complex of natural product rosin derivative: DNA binding, DNA cleavage and cytotoxicity.

Authors:  Bao-Li Fei; Bin Yin; Dong-Dong Li; Wu-Shuang Xu; Yang Lu
Journal:  J Biol Inorg Chem       Date:  2016-09-14       Impact factor: 3.358

3.  Design, Synthesis, DNA/HSA Binding, and Cytotoxic Activity of Half-Sandwich Ru(II)-Arene Complexes Containing Triarylamine-Thiosemicarbazone Hybrids.

Authors:  Mathiyan Muralisankar; Ramachandran Dheepika; Jebiti Haribabu; Chandrasekar Balachandran; Shin Aoki; Nattamai S P Bhuvanesh; Samuthira Nagarajan
Journal:  ACS Omega       Date:  2019-07-05

4.  Design, Synthesis, and Biological Evaluation of Benzimidazole-Derived Biocompatible Copper(II) and Zinc(II) Complexes as Anticancer Chemotherapeutics.

Authors:  Mohamed F AlAjmi; Afzal Hussain; Md Tabish Rehman; Azmat Ali Khan; Perwez Alam Shaikh; Rais Ahmad Khan
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

5.  Synthesis and toxicity assessment of Fe3O4 NPs grafted by ∼ NH2-Schiff base as anticancer drug: modeling and proposed molecular mechanism through docking and molecular dynamic simulation.

Authors:  Rahime Eshaghi Malekshah; Bahareh Fahimirad; Mohammadreza Aallaei; Ali Khaleghian
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

6.  Ruthenium (II) complex cis-[RuII2-O2CC7H7O2)(dppm)2]PF6-hmxbato induces ROS-mediated apoptosis in lung tumor cells producing selective cytotoxicity.

Authors:  Mônica Soares Costa; Yasmim Garcia Gonçalves; Bruna Cristina Borges; Marcelo José Barbosa Silva; Martin Krähenbühl Amstalden; Tássia Rafaella Costa; Lusânia Maria Greggi Antunes; Renata Santos Rodrigues; Veridiana de Melo Rodrigues; Eduardo de Faria Franca; Mariana Alves Pereira Zoia; Thaise Gonçalves de Araújo; Luiz Ricardo Goulart; Gustavo Von Poelhsitz; Kelly Aparecida Geraldo Yoneyama
Journal:  Sci Rep       Date:  2020-09-21       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.